Expanded regimens associated with improved treatment response in MDR-TB

December 29, 2015

Treating multidrug-resistant tuberculosis (MDR TB) with regimens that include a greater number of drugs may improve outcomes, and baseline drug susceptibility testing (DST) could identify drugs with the greatest likelihood of success, according to a paper published this week in PLOS Medicine. The prospective cohort study, conducted by Peter Cegielski of the Centers for Disease Control, Atlanta, Georgia, and colleagues, used information on regimen composition, baseline DST, and time to sputum conversion from 1,137 adults with MDR TB, from nine countries.

The World Health Organization (WHO) guidelines for the treatment of multidrug-resistant tuberculosis (MDR TB) recommend a regimen consisting of at least five potentially effective drugs. However, the researchers found that receiving an average of at least six potentially effective drugs per day was associated with a 36% (adjusted hazard ratio [aHR] 1.36, 95% CI 1.09-1.69) greater likelihood of responding to treatment (defined by time to initial sputum culture conversion) than receiving an average of at least five but fewer than six potentially effective drugs per day. Inclusion of more drugs to which baseline drug susceptibility testing (DST) results indicated susceptibility was associated with a 65% higher likelihood of sputum culture conversion per drug (aHR 1.65, 95% CI 1.48-1.84, per drug), and inclusion of pyrazinamide was associated with a doubling of the likelihood of sputum culture conversion (aHR 2.00, 95% CI 1.65-2.41). Surprisingly, including an additional drug to which baseline DST results indicated resistance was associated with a 33% higher likelihood of sputum culture conversion per drug (aHR 1.33, 95% CI 1.18-1.51, per drug). Inclusion of more drugs for which DST had not been performed was beneficial only if the regimen already contained a minimum of three likely effective drugs.

The authors caution that this is an observational study and cannot prove that increasing the number of drugs in treatment regimens or basing drug choice on DST results improves outcomes. Patients who received a particular treatment may have another shared characteristic that affected the disease outcome, other than those that the authors were able to adjust for in their analysis. The study is also limited by the use of initial sputum conversion and does not provide any information on risk of relapse, and that they were not able to assess the effects of individual drugs.

However, these results suggest changes to the current WHO guidelines for the treatment of MDR TB might be beneficial. The authors say: "... our analysis suggests that MDR TB regimens including more potentially effective drugs than the minimum of five currently recommended by WHO may encourage improved response to treatment in patients with MDR TB. In addition, rapid access to high quality DST results could facilitate the design of more effective individualized regimens."
Research Article


This work was supported by the U.S. Agency for International Development, U.S. Centers for Disease Control and Prevention (CDC), U.S. National Institutes of Health's Division of Intramural Research of the National Institute for Allergy and Infectious Diseases, and the Korean Ministry of Health and Welfare. CDC Division of Tuberculosis Elimination led the study design, training for data collection and monitoring, data analysis, data interpretation, and writing of the report. Other sponsors had no roles in these activities. The views and opinions expressed in this article are those of the authors and do not necessarily represent an official position of the U.S. Centers for Disease Control and Prevention.

Competing Interests:

The authors have declared that no competing interests exist.


Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, et al. (2015) Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. PLoS Med 12(12): e1001932. doi:10.1371/journal.pmed.1001932

Author Affiliations:

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Tropical Disease Foundation, Manila, Philippines
Medical Research Council, Pretoria, South Africa
National Institute of Health, Lima, Peru
Partners In Health, Boston, Massachusetts, United States of America
Socios en Salud Sucursal, Lima, Peru
Riga East University Hospital Centre of Tuberculosis and Lung Diseases, Riga, Latvia
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
Korean Institute of Tuberculosis, Seoul, Republic of Korea
Department of Disease Control, Ministry of Public Health, Bangkok, Thailand
Orel Oblast Tuberculosis Dispensary, Orel, Russian Federation
Vladimir Oblast Tuberculosis Dispensary, Vladimir, Russian Federation
Taiwan Centers for Disease Control, Taipei, Taiwan
Tartu University Hospital, Tartu, Estonia
Central Tuberculosis Research Institute, Russian Academy of Medical Sciences, Moscow, Russian Federation




Peter Cegielski gzc2@cdc.gov


Related Drugs Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

Read More: Drugs News and Drugs Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.